Weiping Jia

80PUBLICATIONS
190CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Electrochemical energy storage and conversionPreventative health careLiquid biopsiesExercise physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (80)

|May 25, 2026
GPSM1 restricts CD73+CD103+ Treg cells in adipose tissue, critical for promoting obesity-related metabolic deterioration.

|May 08, 2026
Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).

|Feb 11, 2026
PRIMARY-AI: outcomes-based standards to safeguard primary care in the AI era.

Dian Zeng, Lorainne Tudor Car, Kamlesh Khunti

|Feb 11, 2026
Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double-blind, placebo-controlled trial (LIGHT 2).

Weiping Jia, Qinghua Wang

|Jan 06, 2026
Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight (LIGHT 1): A randomized, double-blind, placebo-controlled, ascending-dose phase 2a trial.

Fei Gao, Mingxia Yuan, Nianrong Mi

|Dec 30, 2025
Guidelines on primary healthcare for type 2 diabetes in China, 2025.

Weiping Jia, Dalong Zhu, Lixin Guo

Pageof 14

Frequent Collaborators

13 joint publications

Huating Li

10 joint publications

Yuqian Bao

8 joint publications

Cheng Hu

8 joint publications

Bin Sheng